Japan Tobacco Corporation Reports Strong Financial Growth in Q2 2024

Aug.02.2024
Japan Tobacco Corporation Reports Strong Financial Growth in Q2 2024
Japan Tobacco Inc. (JT) reported a significant financial growth in Q2 2024, with operating income up 14%.

On August 2nd, Japan Tobacco Inc. (JT) released its financial report for the second quarter and first half of 2024, showing significant financial growth for the company in the quarter. In the second quarter, operating income increased by 14% year-on-year to 829.6 billion yen (approximately 55.8 billion USD); net profit also increased by 3.9% year-on-year to 147.9 billion yen (approximately 1 billion USD). For the first six months of the year, operating income increased by 12.7% compared to the same period in 2023, reaching 15,699 billion yen (approximately 106 billion USD); net profit increased by 6.3% year-on-year to 305.2 billion yen (approximately 20.5 billion USD).

Japan Tobacco Corporation Reports Strong Financial Growth in Q2 2024
Financial report for the second quarter and first half of 2024 | Source: JT


Key Financial Highlights for JT in the Second Quarter of 2024 (compared to the second quarter of 2023):


Total revenue increased by 14.0% to reach 829.6 billion yen. Core revenue (calculated at a constant exchange rate) grew by 6.7% to reach 745.7 billion yen. Adjusted operating profit (calculated at a constant exchange rate) increased by 2.0% to reach 223.8 billion yen. Operating profit increased by 4.7% to reach 216.8 billion yen. Net profit increased by 3.9% to reach 147.9 billion yen. Key financial highlights for the first half of 2024 for JT (compared to the first half of 2023) include:


Overall revenue increased by 12.7% to 156.99 billion yen. Core revenue, calculated at constant exchange rates, grew by 6.2% to 142.24 billion yen. Adjusted operating profit, also calculated at constant exchange rates, increased by 2.7% to 45.48 billion yen. Operating profit grew by 4.6% to 43.27 billion yen. Net profit increased by 6.3% to 30.52 billion yen.


Forecast adjustment for the full year 2024:


Income is expected to increase by 930 billion yen, with a full year growth of 9.4%. Core income (calculated at a constant exchange rate) is expected to increase by 200 billion yen, with a full year growth of 4.7%. Adjusted operating profit (calculated at a constant exchange rate) is expected to increase by 170 billion yen, with a full year growth of 2.3%. Operating profit is expected to increase by 120 billion yen, but decrease by 1.8% year-on-year. Net profit is expected to increase by 200 billion yen, but decrease by 1.5% year-on-year. Free cash flow is expected to decrease by 677 billion yen. Masamichi Terabatake, President and CEO of the JT Group, stated:


JT Group performed well in the first half of the year, with strengthened market share and pricing strategies driving growth in the tobacco business. Total sales volume increased by 2.0% year-on-year, with combustible products growing by 1.7% and HNB products (RRP) growing by 25.5%. Particularly in the Japanese market, Ploom sales increased by 36% and expanded in 21 markets globally, with sales steadily rising.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
Following recent FDA authorizations for JUUL2 and ZYN ULTRA, 2Firsts Compliance Solutions held an online PMTA briefing on Sept. 4 to examine what the decisions may signal about review efficiency, scientific evidence and U.S. market access. Nearly 30 participants from brands, manufacturers, compliance service providers and investment firms joined the discussion.
2Firsts Events
Sep.06
Reuters Tracks Big Tobacco’s Shift Beyond Cigarettes as Nicotine Pouches Vie for the Next Growth Curve
Reuters Tracks Big Tobacco’s Shift Beyond Cigarettes as Nicotine Pouches Vie for the Next Growth Curve
As cigarette markets face long-term pressure, major tobacco companies are increasingly turning to nicotine pouches in search of growth beyond combustible tobacco. Reuters has examined whether nicotine pouches can become the next strategic growth platform for companies including Philip Morris International, British American Tobacco and Japan Tobacco. PMI strengthened its position through the acquisition of Swedish Match and its ZYN brand, while BAT and JTI continue expanding their own nicotine pouch portfolios. The category has gained attention because of its smoke-free, device-free format, but regulation, youth-use concerns and market scale will determine whether it can become a long-term growth engine.
Regulations
Aug.18 by 2Firsts Perspectives
Earnings Analysis | CTIHK H1 2026 Revenue Falls 26.9% as Core Businesses Diverge and New Growth Drivers Remain to Be Proven
Earnings Analysis | CTIHK H1 2026 Revenue Falls 26.9% as Core Businesses Diverge and New Growth Drivers Remain to Be Proven
China Tobacco International (HK) reported a 26.9% revenue decline in H1 2026, while gross profit fell only 9.5%, revealing sharp divergence across its businesses. Tobacco leaf imports contracted, while leaf exports and Brazil operations expanded strongly. Cigarette exports faced China duty-free market transition, and new tobacco products remained small. Meanwhile, CTIHK continues to strengthen its role as an investment and financing platform, though major external deals have yet to emerge. 2Firsts examines what these shifts mean for its next growth drivers.
Capital Markets
Aug.24
From Nicotine Pouches to Soft Candy Forms: China Tobacco Hubei explores adjustable-release oral nicotine products
From Nicotine Pouches to Soft Candy Forms: China Tobacco Hubei explores adjustable-release oral nicotine products
China-based China Tobacco Hubei Industrial Co., Ltd. has filed a patent application covering an oral nicotine product and its preparation method. The patent proposes a soft candy-shaped oral nicotine product containing nicotine ingredients, gelling agents, sweeteners and alkaline pH regulators. Through formulation adjustments and homogeneous or dual-layer structures, the technology aims to achieve different nicotine release profiles. The filing reflects exploration of new oral nicotine product formats and controlled nicotine delivery approaches.
Aug.06
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia’s Department of Home Affairs has hired Deloitte to provide data analytics, business-process, communications and project-delivery support to the Office of the Illicit Tobacco and E-Cigarette Commissioner. The government says Deloitte personnel do not provide policy advice to the Commissioner or the Australian government, with policy development and decision-making remaining with public officials. The arrangement has nevertheless drawn scrutiny because Deloitte has previously provided professional services to several tobacco and vaping companies.
Sep.03
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26